LAG3 Expression in Triple Negative Breast Cancer
Not Applicable
Recruiting
- Conditions
- Triple Negative Breast CancerImmune Checkpoint Inhibitor
- Registration Number
- NCT06259162
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 128
Inclusion Criteria
- Planned neoadjuvant chemotherapy
- Triple negative breast cancer
Exclusion Criteria
- HER2-positive breast cancer
- Hormone receptor positive breast cancer
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method LAG-3 expression/immune checkpoint preotein expression Before chemotherapy, 1 weeks & 3 weeks after chemotherapy, curative surgery Relationship neoadjuvant chemotherapy plus immune checkpoint inhibitor
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the role of LAG3 in the immune response to triple negative breast cancer when combined with neoadjuvant chemotherapy and immune checkpoint inhibitors?
How does the expression of LAG3 and other immune checkpoint proteins influence the efficacy of neoadjuvant chemotherapy in triple negative breast cancer patients?
What are the potential biomarkers that can predict patient response to LAG3-targeted immune checkpoint inhibitors in triple negative breast cancer?
What are the known adverse events associated with LAG3 inhibition in combination with immune checkpoint inhibitors for triple negative breast cancer treatment?
How do LAG3 inhibitors compare to other immune checkpoint inhibitors in the treatment of triple negative breast cancer?
Trial Locations
- Locations (1)
Ji-Yeon Kim
🇰🇷Seoul, Korea, Republic of
Ji-Yeon Kim🇰🇷Seoul, Korea, Republic ofJi-Yeon KimContact